title: Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer.
abstract: The present study was aim to investigate the prognostic role of platelet to lymphocyte ratio (PLR) for patients with gastric cancer (GC) using meta-analysis. A total of 13 studies (14 cohorts) with 6,280 subjects were included. By pooling hazard ratios (HRs) and 95% confidence intervals (CIs) and odds ratios (ORs) and 95% CIs from each study, we found that elevated PLR was significantly associated with poorer overall survival (OS) (HR: 1.3, 95% CI: 1.1-1.52, p = 0.001; Ι² = 68.5%, Ph < 0.001) but not with poor disease-free survival (DFS) (HR: 1.6, 95% CI: 0.88-2.9, p = 0.122; I2 = 87.8%, Ph < 0.001). Subgroup analysis showed that a high PLR significantly predicted poor OS in Caucasian populations, patients receiving chemotherapy and patients at advanced stage. In addition, the cut-off value of PLR > 160 showed adequately prognostic value. Furthermore, elevated PLR was associated with lymph node metastasis and CEA levels in GC. Our meta-analysis showed that elevated PLR could be a significant prognostic biomarker for poor OS in patients with GC.
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
authors.forename: Xiaobin
authors.initials: X
authors.lastname: Gu
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
authors.forename: Xian-Shu
authors.initials: XS
authors.lastname: Gao
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Cui
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
authors.forename: Mu
authors.initials: M
authors.lastname: Xie
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
authors.forename: Chuan
authors.initials: C
authors.lastname: Peng
authors.affiliation: Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Bai
authors.affiliation: Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Guo
authors.affiliation: Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China.
authors.forename: Linjun
authors.initials: L
authors.lastname: Han
authors.affiliation: Department of Breast Cancer Radiotherapy, Tumor Hospital of Shanxi Provence, Taiyuan, China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Gu
authors.affiliation: Department of Oncology, Tangshan People's Hospital, Hebei, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Xiong
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001792:Blood Platelets / Q000166:cytology*; D015331:Cohort Studies; D018572:Disease-Free Survival; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000166:cytology*; D016017:Odds Ratio; D010976:Platelet Count; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000097:blood* / Q000175:diagnosis*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
keywords: PLR; biomarker; gastric cancer; meta-analysis; prognosis